Leadartis successfully accomplishes the TERET project

07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for Degenerative Retina Diseases) project funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS program. The aim of TERET was the development of the next generation of angiogenic blockers where new compounds with greater efficacy and reduced side effects without compromising eye visual acuity of the patients are essential.

The consortium involved companies and public and private research centers aimed to the identification of potential treatments for the treatment of degenerative diseases of the retina including multivalent antibodies grounded on Leadartis proprietary Trimerbody® technology.

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...